Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy

ClinicalTrials.gov ID

NCT04257396

Lead Sponsor

British Columbia Cancer AgencyOTHER

Overall Status

Unknown status

Study Type

Interventional

Phase

Not Applicable

Enrollment

220Estimated

Last Update Posted

Jan 25, 2023Actual

Start Date

Jun 11, 2020Actual

Primary Completion Date

Jul 31, 2024Estimated

Completion Date

Dec 31, 2024Estimated

Official Title

Multicentre Randomized Controlled Trial Of A Carbon-Fibre Adjustable Reusable Accessory (CARA) For Supine Breast Positioning To Reduce Toxicity In Whole Breast Adjuvant Radiotherapy

Brief Summary

This trial is designed to assess the efficacy of a novel carbon-fibre adjustable reusable accessory (CARA) for breast support to reduce skin toxicity and unwanted normal tissue dose in comparison to the current clinical standard for supine breast support during whole breast RT.

Detailed Description

This study is designed to assess the effectiveness of utilizing the CARA positioning device for reducing the incidence and severity of acute skin reactions in the infra-mammary fold in patients undergoing WBRT. Secondary outcomes include patient reported outcomes and dose to normal body tissue and organs at risk. This is a randomized controlled trial. Participants will be randomly assigned to the following two arms:

Arm 1 patients will receive CARA breast support. The known benefits to using CARA for breast positioning are reduction in IMF skin folds during treatment, reduction in breast separation, and reduction in V50% body, V105% body and lung V20 Gy in treatment planning. No known risks to using CARA have been identified.

Arm 2 patients will not receive CARA breast support. Patients in arm 2 may be treated with no breast support, a small foam wedge, a thermoplastic shell or alternate supine breast support method according to the current standard of care at the treating centre. These methods have entered RT clinical practice over decades of practice without published evidence of impact on rates of MD. Published rates of MD for the control arm thus pertain to a cross section of these methods. The control arm of this study will look at all of these methods combined. There may be centre specific preference for the control method and stratification by centre will be done.

• Adjuvant Radiotherapy for Breast Cancer

• Carbon-Fibre Adjustable Reuseable Accessory (CARA)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age 18 or older.
• Able to provide informed consent
• ECOG performance status 0 - 2
• Stage 0-3 invasive breast cancer or DCIS scheduled to received adjuvant radiotherapy to the whole breast
• Any infra-mammary skin fold of >= 0.5 cm in the supine treatment position and/or palpable lateral breast tissue falling posterior to the mid-axilla line while in supine or treatment position.

Exclusion Criteria:

• Inability to give informed consent or comply with experimental arm of trial
• Previous RT to either breast or to the chest
• Planned boost to infra mammary area
• Use of Mepitel while on treatment
• Failure to heal surgical wound or significant post-operative wound infection
• Presence of significant connective tissue disease (e.g. systemic sclerosis, SLE)
• Known radiation hypersensitivity phenotype (e.g. ataxia telangiectasia etc.)
• Breast reconstruction
• Planned partial breast irradiation, unless the treated area includes the infra-mammary fold

Primary Purpose

Other

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Single

Lead Sponsor

British Columbia Cancer AgencyOTHER

Collaborators

Canadian Cancer Society (CCS)OTHER

cduzenli@bccancer.bc.ca604877-6000 ext. 2021

• CARA Treatment Pilot Study for Breast Positioning

  NCT04543851

  CompletedInterventionalNot ApplicableUpdated Sep 10, 2020
• Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

  NCT05403736

  CompletedInterventionalNot ApplicableUpdated Feb 6, 2025
• Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy

  NCT03768492

  Active, not recruitingInterventionalPhase 2Updated Jun 4, 2026
• Trial Comparing Prone and Supine Intensity-modulated Radiotherapy (IMRT) After Breast-conserving Surgery in Patients With Large Breast Volume at High Risk for Skin Toxicity and Fibrosis

  NCT00887523

  CompletedInterventionalNot ApplicableUpdated Dec 20, 2022
• Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients

  NCT04300829

  Unknown statusInterventionalPhase 3Updated Feb 4, 2021
• A Study of StrataXRT in the Prevention of Radiation Dermatitis in Breast Cancer Patients

  NCT05594498

  Active, not recruitingInterventionalNot ApplicableUpdated May 30, 2025